» Articles » PMID: 35129637

Murine Myeloid Derived Suppressor Cells Possess a Range of Suppressive Mechanisms-Granzyme B is Not Among Them

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

This paper addresses the controversy of Granzyme B (GzmB) expression by murine Myeloid Derived Suppressor Cells (MDSCs). MDSCs are a heterogenous immature myeloid population that are generated in chronic inflammatory pathologies for the purpose to suppress inflammatory responses. MDSCs express a multitude of factors to induce suppressive function such as PD-L1, reactive oxygen species (ROS), nitric oxide synthase (iNOS), and Arginase-1. Recently, Dufait et al. sought to demonstrate GzmB as an additional mechanism for suppression by MDSCs. They reported that murine MDSCs not only significantly express GzmB as well as Perforin (Prf1), but this expression is functionally important for tumor growth in vivo as well as tumor migration in vitro. We conducted experiments to address the same question but made confounding observations: MDSCs under stringent developmental process do not express GzmB. Our results show that not only GzmB protein is not produced at functional level, but the mRNA transcript is not detectable either. In fact, the GzmB protein found in the media of MDSC culture was due to T cells or natural killer cells contained in bone marrow and cultured alongside MDSCs. We strengthen this finding by genetically deleting GzmB from the myeloid lineage and measuring tumor burden compared to WT counterpart. Our results show no significant difference in tumor burden, suggesting that even if there is minor expression of GzmB, it is not produced at a functional amount to affect tumor growth. Therefore, this paper proposes alternative theories that align with the known understanding of GzmB expression and secretion.

Citing Articles

CD27 signaling inhibits tumor growth and metastasis via CD8 + T cell-independent mechanisms in the B16-F10 melanoma model.

Puppala E, Wu L, Fan X, Cao X Cancer Immunol Immunother. 2024; 73(10):198.

PMID: 39105866 PMC: 11303370. DOI: 10.1007/s00262-024-03780-9.


Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials.

Thompson R, Cao X Front Immunol. 2024; 15:1392535.

PMID: 38846935 PMC: 11153694. DOI: 10.3389/fimmu.2024.1392535.


Adjuvant conditioning induces an immunosuppressive milieu that delays alloislet rejection through the expansion of myeloid-derived suppressor cells.

Ge J, Pan W, Feeney N, Ott L, Anderson E, Alessandrini A Am J Transplant. 2023; 23(7):935-945.

PMID: 37080464 PMC: 10330215. DOI: 10.1016/j.ajt.2023.04.015.


Murine regulatory T cells utilize granzyme B to promote tumor metastasis.

Tibbs E, Kalari Kandy R, Jiao D, Wu L, Cao X Cancer Immunol Immunother. 2023; 72(9):2927-2937.

PMID: 36826509 PMC: 10690887. DOI: 10.1007/s00262-023-03410-w.

References
1.
Kumar R, Yoneda J, Fidler I, Dong Z . GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol. 1999; 65(1):102-8. DOI: 10.1002/jlb.65.1.102. View

2.
Danciu C, Falamas A, Dehelean C, Soica C, Radeke H, Barbu-Tudoran L . A characterization of four B16 murine melanoma cell sublines molecular fingerprint and proliferation behavior. Cancer Cell Int. 2013; 13:75. PMC: 3750233. DOI: 10.1186/1475-2867-13-75. View

3.
Dufait I, Pardo J, Escors D, De Vlaeminck Y, Jiang H, Keyaerts M . Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. Cancers (Basel). 2019; 11(6). PMC: 6627828. DOI: 10.3390/cancers11060808. View

4.
Hirst C, Buzza M, Sutton V, Trapani J, Loveland K, Bird P . Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. Mol Hum Reprod. 2001; 7(12):1133-42. DOI: 10.1093/molehr/7.12.1133. View

5.
Kim W, Kim H, Suk K, Lee W . Macrophages express granzyme B in the lesion areas of atherosclerosis and rheumatoid arthritis. Immunol Lett. 2007; 111(1):57-65. DOI: 10.1016/j.imlet.2007.05.004. View